Outlook for the treatment and prognosis of high-grade brain gliomas


  • Yuriy Chomolyak Department of Neurology, Neurosurgery and Psychiatry, Uzhhorod National University, Uzhhorod, Ukraine
  • Volodymyr Smolanka Department of Neurology, Neurosurgery and Psychiatry, Uzhhorod National University, Uzhhorod; Regional Center of Neurosurgery and Neurology, Uzhhorod, Ukraine
  • Taras Studenyak Department of Neurology, Neurosurgery and Psychiatry, Uzhhorod National University, Uzhhorod; Regional Center of Neurosurgery and Neurology, Uzhhorod, Ukraine




high-grade gliomas, glioblastoma, anaplastic astrocytoma, anaplastic oligodendroglioma, oligoastrocytoma, cytoreduction, targeted therapy, biomarkers


Malignant gliomas account up to 38% of primary brain tumors and tend to grow up for the last 30 years. The median survival time for patients with glioblastomas after surgery, followed by a combination of radiation and chemotherapy is 14.6 months. The standard for surgical treatment of malignant gliomas is their maximal safe resection. Increase resection provides patients’ survival increasing, but there are no randomized controlled trials on this subject. For the last years significant progress was marked in understanding of pathogenesis mechanisms of malignant gliomas that opens new possibilities for their treatment improvement. The purpose of the report was to analyze the modern advances in treatment of patients with high-grade brain gliomas and to identify promising directions for future researches. Modern features of surgical treatment as well as additional methods (radiation and chemotherapy) were considered, promising researches were identified.


1. Louis D, Ohgaki H, Wiestler O, Cavenee W, Burger PC, Jouvet A, Scheithauer BW, Kleihues P. The 2007 WHO Classification of Tumours of the Central Nervous System. Acta Neuropathol. 2007;114(2):97-109. [CrossRef] [PubMed]

2. Dolecek TA, Propp JM, Stroup NE, Kruchko C. CBTRUS statistical report: primary brain and central nervous system tumors diagnosed in the United States in 2005-2009. Neuro Oncol. 2012 Nov;14 suppl 5:1-49. [CrossRef] [PubMed]

3. Ohgaki H, Kleihues P. Population-based studies on incidence, survival rates, and genetic alterations in astrocytic and oligodendroglial gliomas. J Neuropathol Exp Neurol. 2005 Jun;64(6):479-89. [PubMed]

4. Mehta M, Vogelbaum MA, Chang S, Patel N. Neoplasms of the central nervous system. In: DeVita VT Jr., Lawrence TS, Rosenberg SA, editors. Cancer: Principles and Practice of Oncology. Philadelphia, Pa: Lippincott Williams & Wilkins; 2011. p.1700–49.

5. Maher EA, McKee AC. Neoplasms of the central nervous system. In: Skarin AT, CanellosGP, editors. Atlas of diagnostic oncology. London: Elsevier Sciense Ltd; 2003.

6. Fisher J, Schwartzbaum J, Wrensch M, Wiemels J. Epidemiology of Brain Tumors. Neurol Clin. 2007;25(4):867-90. [CrossRef] [PubMed]

7. Stupp R, Mason WP, van den Bent MJ, Weller M, Fisher B, Taphoorn MJ, Belanger K, Brandes AA, Marosi C, Bogdahn U, Curschmann J, Janzer RC, Ludwin SK, Gorlia T, Allgeier A, Lacombe D, Cairncross JG, Eisenhauer E, Mirimanoff RO. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med. 2005 Mar 10;352(10):987-96. [PubMed]

8. Walker MD, Green SB, Byar DP, Alexander E Jr, Batzdorf U, Brooks WH, Hunt WE, MacCarty CS, Mahaley MS Jr, Mealey J Jr, Owens G, Ransohoff J 2nd, Robertson JT, Shapiro WR, Smith KR Jr, Wilson CB, Strike TA. Randomized comparisons of radiotherapy and nitrosoureas for the treatment of malignant glioma after surgery. N Engl J Med. 1980 Dec 4;303(23):1323-9. [PubMed]

9. Cardinale R, Won M, Choucair A, Gillin M, Chakravarti A, Schultz C, Souhami L, Chen A, Pham H, Mehta M. A phase II trial of accelerated radiotherapy using weekly stereotactic conformal boost for supratentorial glioblastoma multiforme: RTOG 0023. Int J Radiat Oncol Biol Phys. 2006;65(5):1422-8. [CrossRef]

10. Bennet H, Godlee R. Excision of a tumour from the brain. Lancet. 1888;2:906.

11. Ryken T, Frankel B, Julien T, Olson J. Surgical management of newly diagnosed glioblastoma in adults: role of cytoreductive surgery. J Neurooncol. 2008;89(3):271-86. [CrossRef] [PubMed]

12. Metcalfe SE, Grant R. Biopsy versus resection for malignant glioma. Cochrane Database Syst Rev. 2001;3:CD002034. [PubMed]

13. Dutch Society for Neuro-Oncology; Postma TJ, Bromberg JEC, den Hoed D, Postma TJ, Taphoorn MJB, Dirven CMF, Leenstra S, Heesters M, van der Maazen RWM, van Groeningen CJ, Richel RJ, Kros JM, Wesseling P, Lycklama а Nijeholt GJ. Gliomas — Amsterdam: The Netherlands: Association of Comprehensive Cancer Centres; 2008

14. Alberta Provincial CNS Tumour Team. Glioblastoma: Clinical practice guideline. Edmonton (Alberta): Alberta Health Services, Cancer Care; 2010.

15. Stummer W, Pichlmeier U, Meinel T, Wiestler O, Zanella F, Reulen H. Fluorescence-guided surgery with 5-aminolevulinic acid for resection of malignant glioma: a randomised controlled multicentre phase III trial. Lancet Oncol. 2006;7(5):392-401. [CrossRef] [PubMed]

16. Lacroix M, Abi-Said D, Fourney DR, Gokaslan ZL, Shi W, DeMonte F, Lang FF, McCutcheon IE, Hassenbusch SJ, Holland E, Hess K, Michael C, Miller D, Sawaya R. A multivariate analysis of 416 patients with glioblastoma multiforme: prognosis, extent of resection, and survival. J Neurosurg. 2001 Aug;95(2):190-8. [PubMed]

17. Laws E, Parney I, Huang W et al. Survival following surgery and prognostic factors for recently diagnosed malignant glioma: data from the Glioma Outcomes Project. J Neurosurg. 2003;99(3):467-73. [CrossRef] [PubMed]

18. Chang SM, Parney IF, Huang W, Anderson FA Jr, Asher AL, Bernstein M, Lillehei KO, Brem H, Berger MS, Laws ER; Glioma Outcomes Project Investigators. Patterns of care for adults with newly diagnosed malignant glioma. JAMA. 2005 Feb 2;293(5):557-64. [PubMed]

19. Stummer W, van den Bent M, Westphal M. Cytoreductive surgery of glioblastoma as the key to successful adjuvant therapies: new arguments in an old discussion. Acta Neurochir. 2011;153(6):1211-1218. [CrossRef] [PubMed]

20. McGirt M, Chaichana K, Gathinji M, Attenello F, Than K, Ruiz AJ, Olivi A, Quiсones-Hinojosa A. Independent association of extent of resection with survival in patients with malignant brain astrocytoma. J Neurosurg. 2009;110(1):156-62. [CrossRef] [PubMed]

21. Sanai N, Polley M, McDermott M, Parsa A, Berger M. An extent of resection threshold for newly diagnosed glioblastomas. Jf Neurosurg. 2011;115(1):3-8. [CrossRef] [PubMed]

22. Kubben P, ter Meulen K, Schijns O, ter Laak-Poort M, van Overbeeke J, Santbrink H. Intraoperative MRI-guided resection of glioblastoma multiforme: a systematic review. Lancet Oncol. 2011;12(11):1062-70. [CrossRef] [PubMed]

23. Sanai N, Berger M. Operative techniques for gliomas and the value of extent of resection. Neurotherapeutics. 2009;6(3):478-86. [CrossRef] [PubMed]

24. Solheim O, Selbekk T, Jakola A, Unsgård G. Ultrasound-guided operations in unselected high-grade gliomas—overall results, impact of image quality and patient selection. Acta Neurochir. 2010;152(11):1873-86. [CrossRef] [PubMed]

25. Benveniste R, Germano I. Evaluation of factors predicting accurate resection of high-grade gliomas by using frameless image-guided stereotactic guidance. Neurosurg Focus. 2003;14(2):1-4. [CrossRef] [PubMed]

26. Senft C, Bink A, Franz K, Vatter H, Gasser T, Seifert V. Intraoperative MRI guidance and extent of resection in glioma surgery: a randomised, controlled trial. Lancet Oncol. 2011;12(11):997-1003. [CrossRef] [PubMed]

27. Babu R, Cory Adamson D. Fluorescence-guided malignant glioma resections. Current Drug Discov Technol. 2012;9(4):256-67. [CrossRef] [PubMed]

28. Park JK, Hodges T, Arko L, Shen M, Dello Iacono D, McNabb A, Olsen Bailey N, Kreisl TN, Iwamoto FM, Sul J, Auh S, Park GE, Fine HA, Black PM. Scale to predict survival after surgery for recurrent glioblastoma multiforme. J Clin Oncol. 2010 Aug 20;28(24):3838-43. [CrossRef] [PubMed]

29. Hou L, Veeravagu A, Hsu A, Tse V. Recurrent glioblastoma multiforme: a review of natural history and management options. Neurosurg Focus. 2006;20(4):E3. [CrossRef] [PubMed]

30. Chang SM, Butowski NA, Sneed PK, Garner IV.Standard treatment and experimental targeted drug therapy for recurrent glioblastoma multiforme. Neurosurg Focus. 2006 Apr 15;20(4):E4. [PubMed]

31. Selker RG, Shapiro WR, Burger P, Blackwood MS, Arena VC, Gilder JC, Malkin MG, Mealey JJ Jr, Neal JH, Olson J, Robertson JT, Barnett GH, Bloomfield S, Albright R, Hochberg FH, Hiesiger E, Green S; Brain Tumor Cooperative Group. The Brain Tumor Cooperative Group NIH Trial 87-01: a randomized comparison of surgery, external radiotherapy, and carmustine versus surgery, interstitial radiotherapy boost, external radiation therapy, and carmustine. Neurosurgery. 2002 Aug;51(2):343-57. [PubMed]

32. Johannesen T, Norum J, Lote K, Scheie D, Hirschberg H. A cost-minimising analysis of standard radiotherapy and two experimental therapies in glioblastoma. Radiother Oncol. 2002;62(2):227-31. [CrossRef] [PubMed]

33. Chen A, Chang S, Pouliot J et al. Phase I Trial of gross total resection, permanent iodine-125 brachytherapy, and hyperfractionated radiotherapy for newly diagnosed glioblastoma multiforme. Int J Radiat Oncol Biol Phys. 2007;69(3):825-30. [CrossRef]

34. Chino K, Silvain D, Grace A, Stubbs J, Stea B. Feasibility and safety of outpatient brachytherapy in 37 patients with brain tumors using the GliaSite Radiation Therapy System. Med Phys. 2008;35(7):3383-8. [CrossRef] [PubMed]

35. Koga T, Maruyama K, Tanaka M et al. Extended field stereotactic radiosurgery for recurrent glioblastoma. Cancer. 2012;118(17):4193-200. [CrossRef] [PubMed]

36. Combs SE, Widmer V, Thilmann C, Hof H, Debus J, Schulz-Ertner D. Stereotactic radiosurgery (SRS): treatment option for recurrent glioblastoma multiforme (GBM). Cancer. 2005 Nov 15;104(10):2168-73. [PubMed]

37. Thumma SR, Elaimy AL, Daines N, Mackay AR, Lamoreaux WT, Fairbanks RK, Demakas JJ, Cooke BS, Lee CM. Long-term survival after gamma knife radiosurgery in a case of recurrent glioblastoma multiforme: a case report and review of the literature. Case Rep Med. 2012;2012:545492. [CrossRef] [PubMed]

38. McGirt MJ, Than K, Weingart K, Gliadel (BCNU) wafer plus concomitant temozolomide therapy after primary resection of glioblastoma multiforme. J Neurosurg. 2009;110(3):583-8. [CrossRef] [PubMed]

39. Westphal M, Hilt D, Bortey E, Delavault P, Olivares R, Warnke PC, Whittle IR, Jaaskelainen J, Ram Z. A phase 3 trial of local chemotherapy with biodegradable carmustine (BCNU) wafers (Gliadel wafers) in patients with primary malignant glioma. Neuro Oncol. 2003;5(2):79-88. [CrossRef] [PubMed]

40. Clinical Practice Guidelines in Oncology, version 2.2012 [Internet] / National Comprehensive Cancer Network. — National Comprehensive Cancer Network, 2012. — Available at: http://www.nccn.org/professionals/physician_gls/f_guidelines.asp

41. Dunn G, Fecci P, Curry W. Cancer immunoediting in malignant glioma. Neurosurgery. 2012;71(2):201-23. [CrossRef] [PubMed]

42. Sampson JH, Heimberger AB, Archer GE, Aldape KD, Friedman AH, Friedman HS, Gilbert MR, Herndon Ii JE, Mclendon RE, Mitchell DA, Reardon DA, Sawaya R, Schmittling RJ, Shi W, Vredenburgh JJ, Bigner DD. Immunologic escape after prolonged progression-free survival with epidermal growth factor receptor variant III peptide vaccination in patients with newly diagnosed glioblastoma. J Clin Oncol. 2010;28(31):4722-9. [CrossRef]

43. Parsa T, Crane C, Han S. A phase 2 multicenter trial of autologous heat shock protein peptide vaccine (HSPPC-96) for recurrent glioblastoma multiforme (GBM) patients shows improved survival compared to a contemporary cohort controlled for age, KPS and extent of resection. J. Neurosurg. 2012;117:406.

44. Cancer Genome Atlas Research Network. Comprehensive genomic characterization defines human glioblastoma genes and core pathways. Nature. 2008 Oct 23;455(7216):1061-8. [CrossRef] [PubMed]

45. Verhaak RG, Hoadley KA, Purdom E, Wang V, Qi Y, Wilkerson MD, Miller CR, Ding L, Golub T, Mesirov JP, Alexe G, Lawrence M, O'Kelly M, Tamayo P, Weir BA, Gabriel S, Winckler W, Gupta S, Jakkula L, Feiler HS, Hodgson JG, James CD, Sarkaria JN, Brennan C, Kahn A, Spellman PT, Wilson RK, Speed TP, Gray JW, Meyerson M, Getz G, Perou CM, Hayes DN; Cancer Genome Atlas Research Network. Integrated genomic analysis identifies clinically relevant subtypes of glioblastoma characterized by abnormalities in PDGFRA, IDH1, EGFR, and NF1. Cancer Cell. 2010 Jan 19;17(1):98-110. [CrossRef] [PubMed]

46. Tanaka S, Louis DN, Curry WT, Batchelor TT, Dietrich J. Diagnostic and therapeutic avenues for glioblastoma: no longer a dead end? Nat Rev Clin Oncol. 2013 Jan;10(1):14-26. [CrossRef] [PubMed]

47. Lee BS, Amano T, Wang HQ, Pantoja JL, Yoon CW, Hanson CJ, Amatya R, Yen A, Black KL, Yu JS. Reactive oxygen species responsive nanoprodrug to treat intracranial glioblastoma. ACS Nano. 2013 Apr 23;7(4):3061-77. [CrossRef] [PubMed]

48. Kim YW, Koul D, Kim SH, Lucio-Eterovic AK, Freire PR, Yao J, Wang J, Almeida JS, Aldape K, Yung WK. I dentification of prognostic gene signatures of glioblastoma: a study based on TCGA data analysis. Neuro Oncol. 2013 Jul;15(7):829-39. [CrossRef] [PubMed]



How to Cite

Chomolyak, Y., Smolanka, V., & Studenyak, T. (2013). Outlook for the treatment and prognosis of high-grade brain gliomas. Ukrainian Neurosurgical Journal, (3), 4–9. https://doi.org/10.25305/unj.54140



Review articles